Cost Is a Seizure Control Problem

If your patient can't afford Briviact (brivaracetam), they won't take it consistently. And inconsistent anti-seizure medication use means breakthrough seizures — with all the downstream consequences: emergency department visits, lost driving privileges, workplace injuries, and reduced quality of life.

Brand Briviact runs $1,200 to $2,000 per month at retail without assistance. That's a real barrier, even for insured patients with high-deductible plans. This guide covers the financial assistance landscape so you and your staff can help patients access their medication.

What Your Patients Are Actually Paying

The out-of-pocket cost varies widely depending on insurance:

• Well-insured patients (low-deductible commercial plans): $30–$75/month copay, often reducible to $10 with manufacturer card
• High-deductible commercial plans: Full cash price until deductible met — potentially $1,500+/month for several months
• Medicare Part D: Varies by plan, but often $200–$500/month during coverage gap. No manufacturer copay card available.
• Medicaid: Usually covered with low or no copay, but may require PA
• Uninsured: Full retail price of $1,200–$2,000/month without assistance programs

The patients most at risk of non-adherence are typically those on high-deductible commercial plans and Medicare beneficiaries in the coverage gap.

Manufacturer Savings Programs

UCB Briviact Savings Card

This is the most impactful tool for commercially insured patients:

• Eligible patients may pay as little as $10 per prescription
• No physical card required at participating pharmacies
• Patient enrolls at briviact.com/savings
• Covers the difference between insurance copay and $10

Who's NOT eligible: Patients on Medicare, Medicaid, Tricare, VA, or any government-funded program. This is a federal anti-kickback regulation, not a UCB policy.

Practice tip: Have your staff mention the savings card at the time of prescribing. Many patients don't know about it until they hit sticker shock at the pharmacy.

UCB Patient Assistance Program (PAP)

For uninsured or underinsured patients who meet income criteria:

• Provides Briviact at no cost
• Application through briviact.com or UCB patient support
• Requires income documentation
• Medication shipped through a specialty pharmacy

Practice tip: Keep PAP application forms in your office. Having a social worker or care coordinator assist with applications significantly increases completion rates.

Coupon and Discount Card Programs

For patients paying cash or facing high copays, third-party discount programs can help:

• GoodRx, SingleCare, RxSaver, Optum Perks: These negotiate discounted rates at participating pharmacies. Savings vary by location but can reduce cash prices by 10-40%.
• Important: Discount cards typically cannot be combined with insurance or the UCB savings card. They're most useful for uninsured patients who don't qualify for the PAP or are waiting for PAP approval.

For a patient-facing breakdown of all savings options, you can direct patients to our guide: How to Save Money on Briviact.

Generic Alternatives and Therapeutic Substitution

Generic Brivaracetam

Generic brivaracetam oral solution (Lupin) received FDA approval in February 2026. Generic tablets from Aurobindo, Zydus, and MSN have also received approvals but are not yet widely stocked at retail pharmacies.

When available, anticipated pricing is $200–$600/month — a substantial improvement over brand pricing.

Clinical note: For seizure medications, formulation changes warrant monitoring. If switching a stable patient from brand to generic, consider closer follow-up for the first few months to ensure seizure control is maintained.

Therapeutic Alternatives

If cost is the primary barrier and generic brivaracetam isn't yet available:

• Levetiracetam (Keppra) generic: $15–$50/month. Same mechanism (SV2A). Most common reason patients are on Briviact instead is Levetiracetam behavioral side effects — document this clearly in the chart if switching back isn't appropriate.
• Lacosamide (Vimpat) generic: Becoming available, different mechanism (sodium channel), generally well-tolerated. May be a reasonable cost-conscious alternative.

Building Cost Conversations Into Your Workflow

Cost discussions work best when they're systematic, not reactive. Here are workflow suggestions:

• At prescribing: Mention the UCB savings card and provide enrollment information. Takes 30 seconds and prevents the pharmacy cost shock that leads to abandoned prescriptions.
• At follow-up: Ask "Are you having any trouble affording your medications?" This normalizes the conversation and catches issues before they become non-adherence.
• Flag high-risk patients: Patients with high-deductible plans, Medicare Part D, or no insurance should be proactively connected to PAP resources.
• Use your care coordinator: If your practice has a social worker or benefits coordinator, route Briviact patients to them for financial assistance support.

For provider-focused tools and resources, visit Medfinder for Providers.

Final Thoughts

The cost of Briviact doesn't have to be a barrier to good seizure control. Between the UCB savings card ($10 copay for commercial insurance), the patient assistance program (free for qualifying uninsured patients), emerging generics, and discount card programs, there are solutions for most patient situations.

The key is being proactive: discuss cost at the time of prescribing, not after the patient has already failed to fill their prescription. A few minutes spent on financial navigation can prevent seizures, ED visits, and the downstream cascade of uncontrolled epilepsy.

For the clinical availability picture, see: Briviact Shortage: What Providers Need to Know.